PVRL2 rs6859: Understanding This Genetic Variant and Alzheimer's
The rs6859 variant is a single-nucleotide polymorphism located within the PVRL2 gene on chromosome 19. It has been identified in various genome-wide association studies as being statistically associated with susceptibility to late-onset Alzheimer's disease.
What each genotype means
Baseline risk profile
This genotype is considered the baseline or reference state in many studies investigating this variant. Research suggests that individuals with this genotype may have a lower relative risk for Alzheimer's disease compared to those carrying the A allele in certain clinical cohorts.
This is the more common genotype in many populations, with the G allele being the major allele in European ancestry groups.
Increased susceptibility profile
Carrying one copy of the A allele has been associated with an increased risk of developing Alzheimer's disease in some observational studies. This association is independent of the well-known APOE risk factors, though the overall impact remains a subject of ongoing research.
This heterozygous genotype is frequently observed, reflecting the significant prevalence of the A allele in the general population.
Elevated susceptibility profile
Individuals with this genotype have been observed in some studies to have a higher statistical association with incident Alzheimer's disease compared to those with the GG genotype. Because this evidence is based on observational population data, it does not predict individual health outcomes and should be viewed as a small component of a complex genetic landscape.
This genotype is less common than the heterozygous state but is present in a notable portion of individuals of European ancestry.
What is the rs6859 Variant?
The rs6859 variant is a specific change in the DNA sequence, known as a single-nucleotide polymorphism (SNP), located on chromosome 19. This region of the genome is highly significant in human genetics because it houses the APOE gene cluster, a well-known area associated with lipid metabolism and neurological health. The rs6859 variant specifically sits within the PVRL2 gene, which encodes a protein called Nectin-2. Because this variant is physically close to the APOE gene, researchers often study it to determine if it contributes independently to disease risk or if its effects are linked to the nearby APOE alleles. In genetic research, rs6859 is categorized as a trait-associated variant, meaning that statistical analysis of large populations has shown a correlation between the presence of specific alleles at this site and certain health outcomes, such as cognitive decline or Alzheimer's disease risk.
The Role of the PVRL2 Gene
The PVRL2 gene provides instructions for making a protein known as Nectin-2. This protein is a cell adhesion molecule, which means it helps cells stick together and communicate with one another. Nectin-2 is found in various tissues throughout the body, including the brain, where it plays a role in the formation and maintenance of junctions between cells. While the primary function of Nectin-2 is related to cell-to-cell interaction, its proximity to the APOE gene has led scientists to investigate whether variations in this gene might influence brain health. Research into PVRL2 is ongoing, and while it is clear that the protein is essential for normal cellular function, the exact mechanism by which the rs6859 variant might influence Alzheimer's disease risk remains a subject of active scientific inquiry rather than a fully established biological pathway.
Research and Evidence Strength
The evidence linking rs6859 to late-onset Alzheimer's disease is considered limited and primarily based on statistical associations observed in genome-wide association studies (GWAS). Several studies have reported that the 'A' allele of rs6859 is more frequently observed in individuals with Alzheimer's disease or mild cognitive impairment compared to healthy control groups. However, because this variant is located in a region with high linkage disequilibrium—meaning it is often inherited alongside other nearby genetic variations—it can be difficult for researchers to isolate the specific effect of rs6859 from the effects of the neighboring APOE gene. While some studies have suggested that rs6859 may have an independent association with disease progression, these findings are not universally consistent across all populations. Consequently, while the statistical signal is notable, it is not currently used as a definitive diagnostic tool for predicting individual health outcomes.
Population Frequency
The rs6859 variant is a common genetic feature in human populations. Data from large-scale genomic databases indicate that the minor allele frequency for this SNP is approximately 0.35 to 0.39 in European populations. This means that a significant portion of the population carries at least one copy of the variant allele. Because it is so common, it is considered a normal variation in the human genome rather than a rare mutation. Frequency can vary across different ancestral backgrounds, and researchers continue to collect data to better understand how these frequencies differ globally. Understanding these population-level statistics is crucial for scientists to ensure that genetic studies are representative and that associations found in one group are validated in others.
What This Information Means for You
It is important to understand that having a specific genotype at the rs6859 site does not mean an individual will develop Alzheimer's disease. Genetic associations are statistical observations made across large groups of people, not individual medical predictions. Many factors, including lifestyle, environment, and other genetic markers, contribute to complex conditions like Alzheimer's. If you are concerned about your cognitive health or family history, the most appropriate step is to consult with a healthcare professional or a genetic counselor. They can provide context based on your personal health history and help you understand what current research does and does not imply. Never use genetic information to make medical decisions or change medications without first discussing the findings with your clinician or pharmacist, as they are best equipped to interpret these results in the context of your overall health.
How common is this variant?
The rs6859 variant is common, with a minor allele frequency of approximately 0.35 to 0.39 in European populations.
Frequently asked questions
Does having the rs6859 variant mean I will get Alzheimer's?
No. The rs6859 variant is only one of many factors that may influence Alzheimer's risk. It is a statistical association found in research studies and cannot be used to predict whether an individual will develop the disease.
Is rs6859 the same as the APOE gene?
No, rs6859 is a variant located in the PVRL2 gene. However, it is located very close to the APOE gene on chromosome 19, which is why researchers often study them together.
Should I get tested for the rs6859 variant?
Genetic testing for this variant is not a standard clinical practice for diagnosing Alzheimer's disease. If you have concerns about your memory or cognitive health, you should speak with a doctor about appropriate clinical evaluations.
Can I change my risk associated with this variant?
While you cannot change your genetics, many lifestyle factors such as diet, exercise, and cognitive engagement are studied for their potential role in supporting brain health. Discuss any health-related lifestyle changes with your primary care physician.
Sources & further reading
Educational information only, last refreshed 10/10/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6859?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in NECTIN2
Associated with human survival to advanced age and extended healthspan within the APOE-TOMM40-NECTIN2 cluster independent of APOE epsilon 4.
Polymorphism in NECTIN2/PVRL2 linked to centenarian survival and resilience against age-related neurodegenerative progression.
Intronic regulatory variant in NECTIN2 showing significant enrichment in nonagenarians and centenarians in multiple aging cohorts.